Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma
This study identifies ADORA2B as a critical regulator of metastatic progression in UPS, implicating it as a promising therapeutic target. Ongoing clinical trials targeting adenosine pathways further support the translational potential of ADORA2B inhibition to disrupt metastasis and improve outcomes for UPS patients.
Authors
- Vanessa Chaire (ORCID: https://orcid.org/0009-0005-5421-1203)
- A. Italiano
- Lucile Vanhersecke (ORCID: https://orcid.org/0000-0001-7733-7806)
- Alban Giese (ORCID: https://orcid.org/0000-0003-0287-1224)
- Stéphanie Verbeke (ORCID: https://orcid.org/0000-0001-8760-8526)
- Alban Bessede (ORCID: https://orcid.org/0000-0002-6521-8380)
- Raul Perret (ORCID: https://orcid.org/0000-0003-2698-0249)
- V.R. Velasco (ORCID: https://orcid.org/0000-0003-3904-8602)
- François Bertucci (ORCID: https://orcid.org/0000-0002-0157-0959)
- Mariella Spalato Ceruso
- Jean-Philippe Guégan
- Christophe Rey
- Yanina Valverde Timana
Institutions
- Centre National de la Recherche Scientifique (FR)
- Sciences Po Bordeaux (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Bordeaux Population Health (FR)
- Institut Bergonié (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
- Intercytex (United Kingdom) (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3934
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00